

74% MNTR 52 Week Gain since Starting 2013 at \$0.19/sh -- for Comparison

Now at: \$0.33 Annualized MNTR Gain: 73%

97% Index Gain / 52 wks

Cancer Immunotherapy Index - 2013

Annualized Index Gain: 97%

55%

Versus Gain / 52 wks for (NASDAQ:Biotech + S&P Biotech + NYSE Biotech Indices) / 3

Annualized Average of 3 Indices Gain: 55%

Company in CI Index	Symbol	31-Dec Price	31-Dec-12 Start Price	52 week Gain	Market Cap	Cash Eq per Sh	USA Market for Cancer Types	MKT / Mkt Cap
Advaxis, Inc. (Prostate, Cervical, Anal and Head & Neck Cancers)	(ADXS)	\$4.24 <small>(7/17 post-split price)</small>	\$3.75	13%	\$49 M	\$0.00	\$0.1 B	2 x
Dendreon Corporation (Prostate, Breast, Colon, Ovarian, Lung & Kidney, and Cervical Cancers)	(DNDN)	\$2.99	\$5.29	-43%	\$457 M	\$1.09	\$25.8 B	56 x
Oncothyreon (Lung Cancer)	(ONTY)	\$1.76	\$1.92	-8%	\$122 M	\$0.89	\$5.2 B	42 x
Agenus (Formerly Antigenics) (Melanoma & Lung Cancers)	(AGEN)	\$2.64	\$4.10	-36%	\$93 M	\$0.86	\$5.4 B	58 x
Biovest International (Non-Hodgkins Lymphoma -- Bankruptcy Adjustment from 7/15)	(BVTIQ.OB)	\$0.00	\$0.13	-96%	\$1 M	\$0.00	\$3.1 B	4,354 x
Celldex Therapeutics, Inc. (Brain and Multiple Cancers & Monoclonal Antibodies)	(CLDX)	\$24.21	\$6.71	261%	\$1,958 M	\$1.69	\$5.2 B	3 x
ImmunoCellular Therapeutics, Ltd. (Myeloma, Prostate, Peptide Based & Stem Cell)	(IMUC)	\$0.93	\$1.92	-52%	\$53 M	\$0.51	\$9.8 B	185 x
Northwest Biotherapeutics, Inc. (Prostate, Brain, Lung & Ovarian Cancers)	(NWBO.OB)	\$4.55	\$3.12	46%	\$174 M	\$0.08	\$7.2 B	41 x
CEL-SCI Corporation (Head and Neck Cancers & Cytokines)	(CVM)	\$0.59	\$2.70	-78%	\$30 M	\$0.00	\$4.9 B	167 x
Generex Biotechnology Corporation (Breast & Prostate Cancers)	(GNBTOB)	\$0.03	\$0.03	14%	\$18 M	\$0.00	\$2.1 B	119 x
Provectus Pharmaceuticals, Inc. (Melanoma)	(PVCT.OB)	\$2.41	\$0.56	330%	\$336 M	\$0.06	\$0.3 B	1 x
NewLink Genetics Corporation (Lung, Melanoma & Prostate Cancers -- Added 1/1/2013)	(NLNK)	\$22.01	\$12.50	76%	\$563 M	\$1.99	\$5.9 B	10 x
Galena Biopharma Corporation (Breast, Prostate, & Ovarian Cancers -- Added 1/1/2013)	(GALE)	\$4.96	\$1.53	224%	\$521 M	\$0.52	\$7.9 B	15 x
Vical Incorporated (Melanoma -- Added 1/1/2013)	(VICL)	\$1.18	\$2.91	-59%	\$102 M	\$0.64	\$2.4 B	23 x
Inovio Pharmaceuticals, Inc. (Melanoma & Solid Tumor Cancers -- Added 1/1/2013)	(INO)	\$2.90	\$0.50	481%	\$603 M	\$0.22	\$4.8 B	8 x
CANCER IMMUNOTHERAPY INDEX -- 2013 (Reset to \$1,000 Each Jan 1st - Invested Equally in 2009 & Adjusted for Additions)*		\$1,974	\$1,000	97% **	\$5,079 M	20%	\$90.0 B ***	18 x

* Cancer Immunotherapy Index was developed July 10, 2009 by Mr. Billingsley with the support of Mike Havrilla, PhD., Editor of MikeHavRx.com.

** From its inception, July 10, 2009 through to December 31, 2012, the Cancer Immunotherapy Index posted a 13% gain or an average gain of 4% per annum.

*** Market Data from National Cancer Institute based on Relative Mortality in company treatment areas with market shared by all participating companies in their treatment areas.

NO INVESTMENT ADVISORY DISCLAIMER: Readers are cautioned that Mentor Capital, Inc. does not intend this Cancer Immunotherapy Index to be investment advice. The CI Index is a mathematical, information only index and has been published on a regular basis since inception. The original and continuing purpose is to establish a benchmark as to how the cancer immunotherapy sector as a whole has behaved. As such, it presents historic information and does not purport nor imply any opinion or advice on the current or future value of any stock, nor account for trading costs that in practice will reduce investment gains. Always consult with your investment advisor before buying MNTR or CI Index stocks.